Vancouver, British Columbia (Newsfile Corp. - May 31, 2021) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company"), today reported financial results for the quarter ended March 31, 2021.
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2021
News provided by
Share this article
Share this article
- Presented promising preliminary pharmacokinetic and clinical data on EPI-7386 in metastatic castration-resistant prostate cancer at 2021 AACR
- Raised approximately $150 million in a public offering
HOUSTON and VANCOUVER, BC, May 6, 2021 /PRNewswire/ - ESSA Pharma Inc. ( ESSA or the Company ) (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fiscal second quarter ended March 31, 2021. All references to $ in this release refer to United States dollars, unless otherwise indicated.
(2)
Vancouver, British Columbia (Newsfile Corp. - April 29, 2021) - iCo Therapeutics ( iCo or the Company ) (TSXV: ICO) (OTC: ICOTF) today reported financial results for the year ended December 31, 2020. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ( IFRS ).
William Jarosz, CEO of iCo Therapeutics Inc., noted We were very pleased by the progress of our Oral Amp B program during the year with our compound being safe and well tolerated in Phase 1b clinical trials and potential as a therapeutic agent for novel Coronavirus. We are also excited for the new strategic directions that are open for us in this new year with Satellos, and the associated concurrent financing, previously announced.
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2020
News provided by
Share this article
Share this article
VANCOUVER, BC and HOUSTON, Feb. 11, 2021 /PRNewswire/ - ESSA Pharma Inc. ( ESSA , or the Company ) (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fiscal first quarter ended December 31, 2020. All references to $ in this release refer to United States dollars, unless otherwise indicated. ESSA s series of accomplishments over the past calendar year have included raising $48.9 million in an over-subscribed public offering, the granting by the U.S. Food and Drug Administration (the FDA ) of Fast Track Designation to our lead product candidate EPI-7386, and the initiation of a Phase 1 trial with EPI-7386 for patients with metastatic castration-resistant
Ultrack Systems, Inc.: Ultrack Systems Successfully Retires An Initial One Hundred Million Outstanding Common Shares
Concord, Ontario (Newsfile Corp. - February 2, 2021) - Ultrack Systems Inc. (OTC Pink: MJLB), a total fleet-management GPS tracking and monitoring solution provider, is pleased to announce that the Company has successfully completed the process of retiring 100,000,000 shares that are currently issued and considered outstanding with our corporate share structure. After completing this substantial reduction, the new current Outstanding Share total is approximately 275m.
Ultrack CEO Michael Marsbergen commented: These 100,000,000 common share reductions is in keeping with my commitment to shareholders to growing this Company and adding value wherever possible. Retiring 100 million shares from our current Outstanding Share count immediately increases shareholder value. At the current market price of about .07 per share for MJLB stock this retirement represents a $7,0